Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 345-352 , September 2009

Expression of the bifunctional suicide gene CDUPRT increases radiosensitization and bystander effect of 5-FC in prostate cancer cells

  • Ligang Xing

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, PR China
    • ,
  • Xiaorong Sun

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, PR China
    • ,
  • Xuelong Deng

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Khushali Kotedia

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Muneyasu Urano

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Jason A. Koutcher

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • C. Clifton Ling

      Affiliations

    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Gloria C. Li

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, P.O. Box #72, New York, NY 10065, United States.

Received 8 January 2009 ,Revised 9 March 2009 ,Accepted 6 April 2009.

References 

  1. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol. 2001;187:22–36
  2. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther. 1990;48:189–222
  3. Hwang HS, Davis TW, Houghton JA, Kinsella TJ. Radiosensitivity of thymidylate synthase-deficient human tumor cells is affected by progression through the G1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res. 2000;60:92–100
  4. Anello R, Cohen S, Atkinson G, Hall SJ. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation. J Urol. 2000;164:2173–2177
  5. Kievit E, Nyati MK, Ng E, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res. 2000;60:6649–6655
  6. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 1995;55:4808–4812
  7. Kanai F, Kawakami T, Hamada H, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res. 1998;58:1946–1951
  8. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes JP, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett. 1998;167:41–49
  9. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res. 2000;60:3813–3822
  10. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 1981;41:73–81
  11. Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T. The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer. 2007;120:268–277
  12. Xing L, Deng X, Kotedia K, et al. Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein. Acta Oncol (Stockholm, Sweden). 2008;47:1211–1220
  13. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck. 1997;19:567–575
  14. Smith TJ, Ryan LM, Douglass HO, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:269–276
  15. Kievit E, Bershad E, Ng E, et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res. 1999;59:1417–1421
  16. Freytag SO, Movsas B, Aref I, et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther. 2007;15:1016–1023
  17. Corban-Wilhelm H, Ehemann V, Becker G, Greulich D, Braun K, Debus J. Comparison of different methods to assess the cytotoxic effects of cytosine deaminase and thymidine kinase gene therapy. Cancer Gene Ther. 2004;11:208–214
  18. Khil MS, Kim JH, Mullen CA, Kim SH, Freytag SO. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res. 1996;2:53–57
  19. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 1994;91:8302–8306
  20. Corban-Wilhelm H, Hull WE, Becker G, Bauder-Wust U, Greulich D, Debus J. Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy. Gene Ther. 2002;9:1564–1575
  21. Kambara H, Tamiya T, Ono Y, et al. Combined radiation and gene therapy for brain tumors with adenovirus-mediated transfer of cytosine deaminase and uracil phosphoribosyltransferase genes. Cancer Gene Ther. 2002;9:840–845
  22. Hamstra DA, Lee KC, Tychewicz JM, et al. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther. 2004;10:916–928
  23. Gade TP, Koutcher JA, Spees WM, et al. Imaging transgene activity in vivo. Cancer Res. 2008;68:2878–2884

PII: S0167-8140(09)00160-1

doi: 10.1016/j.radonc.2009.04.003

Radiotherapy & Oncology
Volume 92, Issue 3 , Pages 345-352 , September 2009

Article Tools

* Image Usage & Resolution